Date | Product | Disease | Phase | Company | Therapeutic area |
---|---|---|---|---|---|
2011-09-27 | LB03002 (once-a-week, sustained release recombinant human growth hormone (hGH)) | growth hormone deficiency | 3 | Biopartners (Switzerland) LG Life Sciences (Korea) | Hormonal diseases - Endocrine diseases |
2011-09-26 | AP214 | renal protection in cardiac surgery |
2b | Action Pharma (Denmark) | Cardiovascular diseases - Renal diseases - Kidney diseases |
2011-09-26 | Afinitor® (everolimus) | breast cancer | 3 | Novartis (Switzerland) | Cancer Oncology |
2011-09-25 | QTI571 (imatinib) | pulmonary arterial hypertension | 3 | Novartis (Switzerland) | Rare diseases - Cardiovascular diseases - Autoimmune diseases |
2011-09-22 | BIBF 1120* | idiopathic pulmonary fibrosis |
2 | Boehringer Ingelheim (Germany) | Lung diseases |
2011-09-21 | tiotropium plus olodaterol | chronic obstructive pulmonary disease (COPD) |
3 | Boehringer Ingelheim (Germany) | Respiratory diseases |
2011-09-21 | NI-0801 | primary biliary cirrhosis | 2 | NovImmune (Switzerland) | Rare diseases Autoimmune diseases |
2011-09-20 | budesonide MMX® | induction of remission of mild or moderate active ulcerative colitis | 3 | Cosmo Pharmaceutical (Italy) Santarus (USA) | Inflammatory diseases - Autoimmune diseases |
2011-09-19 | TrasGEX™ | breast cancer | 1 | Glycotope (Germany) | Cancer Oncology |
2011-09-19 | Epi proColon® 2.0 (colorectal cancer blood test) | colorectal cancer detection | validation study | Epigenomics (Germany-USA) | Cancer - Oncology |
2011-09-19 | PRC-4016 | combined dyslipidemia | 1 | Pronova BioPharma (Norway) | Metabolic diseases Cardiovascular diseases |
2011-09-19 | ChondroCelect® | symptomatic cartilage defects of the knee | follow-up | Tigenix (Belgium) | Bone diseases |
2011-09-16 | Ixiaro® | Japanese Encephalitis | 3 | Intercell (Austria) Biological E. Ltd (India) | Infectious diseases |
2011-09-16 | ACZ885 (canakinumab) | systemic juvenile idiopathic arthritis (SJIA) | 3 | Novartis (Switzerland) | Autoimmune diseases - Rare diseases |
2011-09-15 | Px-102 | NASH (non-alcoholic steatohepatitis) and other liver diseases |
1 | Phenex Pharmaceuticals (Germany) | Metabolic diseases - Liver diseases |
2011-09-15 | AG013 | prevention of oral mucositis in head and neck cancer patients receiving chemo-induction therapy | 1b | Actogenix (Belgium) | Cancer Oncology |
2011-09-14 | masitinib | asthma | 3 | AB Science (France) | Allergic diseases - Inflammatory diseases - Respiratory diseases |
2011-09-13 | ACP-001 | growth hormone deficiency | 2 | Ascendis Pharma (USA-Denmark) | Hormonal diseases - Endocrine diseases |
2011-09-12 | GFT505 | NASH (non-alcoholic steatohepatitis NAFLD (non-alcoholic fatty liver disease) |
preclinical | Genfit (France) | Liver diseases - Metabolic diseases |
2011-09-07 | MG01CI (extended release formulation of Metadoxine (pyridoxol L-2-pyrrolidone-5-carboxylate) | attention deficit hyperactivity disorder (ADHD) |
2 | Teva Pharmaceutical Industries (Israel) Alcobra (Israel) | CNS diseases - Neurological diseases |